Hitos en el desarrollo de los radiofármacos PET
Resumen
Palabras clave
Referencias
IDO T, WON CN, FOWLER JS, WOLF AP. Fluorination with F2. A Convenient Synthesis of 2-Deoxy-2-fluoo-D-glucose. J. Org. Chem. 1977; 42 (13): 2341-2342.
IDO T, WON CN, CASELLA V, et. al. Labeled 2-deoxy-D-glucose analog. 18F-labeled 2-deoxy-2-fuluoro-D-glucose, 2-deoxy-2-fluoo-D-mannose and 14C-2-deoxy-2-fuluoro-D-glucose. J of Labelled Comp. and Radiopharm. 1978; 16(2): 175-183.
REIVICH M, KUHL D, WOLF A, GREENBERG J, PHELPS M, IDO T, et. al. The [18F]Fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circulation Research. 1979; 44(1): 127-137.
ISHIWATA K, IDO T, KAWAMURA M, et. al. 4-Boron-2-[18F]Fluoro-D,L-phenylalanine as a target compound for boron neutron capture therapy: tumour imaging potential with positron emission tomography. Nucl. Med. Biol. 1991; 18(7): 745-751.
IMAHORI Y, UEDA S, OHMORI Y, KUSAKI T, ONO K, FUJII R, IDO T. Fruorine-18-labeled fluooboronophenylalanine PET in patients with glioma. J. Nucl. Med. 1998; 39(2): 325-333.
TAKAHASHI T, IDO T, IWATA R. Synthesis of 17-[18F]fluoo-5-methylpentadecanoic Acid. Appl. Radiat. Isot. 1992; 43(6): 822-824.
TAKAHASHI T, NISHIMURA S, IDO T, ISHIWATA K, IWATA R. Biological evaluation of 5-Methyl-branched-chain ω-[18F]Fluorofatty acid: a potencial myocardial imaging tracer for positron emission tomography. Nucl. Med. Biol. 1996; 23(3): 303-308.
HATANO K, ISHIWATA K, KAWASHIMA K, HATAZAWA J, ITOH M, IDO T. D2-Dopamine receptor specificbrain uptake of carbon-11-labeled YM-09151-2. J. NUC. Med. 1989; 30(4): 515-522.
ISHIWATA K, YANAI K, IDO T, MIURA Y, KAWASHMA K. Synthesis and biodistribution of [11C] fludiazepam for imaging benzodiazepine receptors. Nucl. Med. Biol. 1988; 15(4): 365-371.
YANAI K, WATANABE T, YOKOYAMA H, MEGRO K, HATAZAWA J, ITOH M, et.al. Histamine H1 receptors in human brain visualized in vivo by [11C]doxepin and emission tomography. Neuroscience Letters. 1992; 137(2): 145-148.
YANAI K, RYU JH, WATANABE T, IWATA R, IDO T, SAWAI Y, et. al. Histamine H1 receptor occupancy in human brain after single doses of histamine H1 antagonist measured by positron emission tomography. British J Pharmacology. 1995; 116(1): 1649-1655.
HOLLAND JP, SHEH Y, LEWIS JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl. Med. Biol. 2009; 36(7): 729-739.
HOLLAND JP, DIVILOV V, BANDER NH, SMIS-JONES PM, LAR-SO N SM, LEVIS JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J. Nucl. Med. 2010; 51(8): 1293-1300.
van de WATERRING FCJ, RIJPKEMA M, PERK L, BRINKMANN U, OYEN WJG, BOERMAN OC. Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients (review). BioMed Res Int. 2014; Article ID 203601 http://www.hindawi.com/journals/bmri/2014/203601.
XIA CF, ARTEAGA J, CHEN G, GANGADHARMATH U, GOMEZ LF, et. al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimer’s and Dementia. 2013; 9(6): 666-676.
VILLEMAGNE VL, OKAMURA N. In vivo tau imaging: obstacle and progress. Alzheimer's and Dementia. 2014; 10(3): 254-264.
HARADA R, OKAMURA N, FURUMOTO S, FURUKAWA K, ISHIKI A, TOMITA N, et. al. [18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur. J. Nucl. Med. Mol. Imaging. 2015; 42(7): 1052-1061.